Status:

COMPLETED

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Kidney Failure, Chronic

Kidney Transplantation

Eligibility:

All Genders

1-20 years

Phase:

PHASE1

Brief Summary

Kidney transplantation is widely considered to be the treatment of choice for children with End Stage Renal Disease (ESRD). The purpose of this study is to determine the safety of sirolimus monotherap...

Detailed Description

Improvements in surgical techniques, donor selection, immunosuppression practices, and the enhanced experience of specialized pediatric transplant teams have all led to marked improvements in patient ...

Eligibility Criteria

Inclusion

  • Participant and/or parent guardian able to understand and willing to provide informed consent
  • Previously enrolled and completed the CCTPT-PC01 study and within the 36 months post-completion timeframe prior to study entry
  • Currently receiving sirolimus and MMF or azathioprine therapy
  • No history of acute rejection episodes
  • No evidence of acute or chronic rejection on the 24 month CCTPT-PC01 protocol biopsy or any subsequent biopsy obtained after that time prior to study entry
  • PRA (Class I and II) less than 5% at study entry
  • No evidence of donor specific antibody at study entry
  • Stable renal function with GFR greater than 60 cc/min 1.73M\^2 using the Schwartz calculated method
  • A negative pregnancy test for female participants of childbearing potential at study entry
  • Agreement by female and male participants to use FDA approved methods of contraception.

Exclusion

  • Total lymphocyte count less than 400 mm\^3
  • Acute or chronic infection at study entry
  • Treatment with investigational drug within 1 month prior to study entry
  • Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the study
  • History of allergic reaction to Iodine GFR assay
  • History of malignancy within the past 12 months
  • Inability or unwillingness to give informed consent or comply with the study protocol

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT00768729

Start Date

May 1 2009

End Date

December 1 2012

Last Update

February 15 2013

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Children's Hospital of Central California

Madera, California, United States

2

UCSF Children's Hospital

San Francisco, California, United States

3

Children's Hospital, Boston

Boston, Massachusetts, United States

4

Children's Hospital, Philadelphia

Philadelphia, Pennsylvania, United States